Fibrinolysis Shutdown in COVID-19: Clinical Manifestations, Molecular Mechanisms, and Therapeutic Implications

The COVID-19 pandemic has introduced a global public health threat unparalleled in our history. The most severe cases are marked by ARDS attributed to microvascular thrombosis. Hypercoagulability, resulting in a profoundly prothrombotic state, is a distinct feature of COVID-19 and is accentuated by...

Descripción completa

Detalles Bibliográficos
Autores principales: Meizoso, Jonathan P., Moore, Hunter B., Moore, Ernest E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: by the American College of Surgeons. Published by Elsevier Inc. 2021
Materias:
Collective Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7982779/
https://www.ncbi.nlm.nih.gov/pubmed/33766727
http://dx.doi.org/10.1016/j.jamcollsurg.2021.02.019
_version_ 1783667791883141120
author Meizoso, Jonathan P.
Moore, Hunter B.
Moore, Ernest E.
author_facet Meizoso, Jonathan P.
Moore, Hunter B.
Moore, Ernest E.
author_sort Meizoso, Jonathan P.
collection PubMed
description The COVID-19 pandemic has introduced a global public health threat unparalleled in our history. The most severe cases are marked by ARDS attributed to microvascular thrombosis. Hypercoagulability, resulting in a profoundly prothrombotic state, is a distinct feature of COVID-19 and is accentuated by a high incidence of fibrinolysis shutdown. The aims of this review were to describe the manifestations of fibrinolysis shutdown in COVID-19 and its associated outcomes, review the molecular mechanisms of dysregulated fibrinolysis associated with COVID-19, and discuss potential implications and therapeutic targets for patients with severe COVID-19.
format Online
Article
Text
id pubmed-7982779
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher by the American College of Surgeons. Published by Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-79827792021-03-23 Fibrinolysis Shutdown in COVID-19: Clinical Manifestations, Molecular Mechanisms, and Therapeutic Implications Meizoso, Jonathan P. Moore, Hunter B. Moore, Ernest E. J Am Coll Surg Collective Review The COVID-19 pandemic has introduced a global public health threat unparalleled in our history. The most severe cases are marked by ARDS attributed to microvascular thrombosis. Hypercoagulability, resulting in a profoundly prothrombotic state, is a distinct feature of COVID-19 and is accentuated by a high incidence of fibrinolysis shutdown. The aims of this review were to describe the manifestations of fibrinolysis shutdown in COVID-19 and its associated outcomes, review the molecular mechanisms of dysregulated fibrinolysis associated with COVID-19, and discuss potential implications and therapeutic targets for patients with severe COVID-19. by the American College of Surgeons. Published by Elsevier Inc. 2021-06 2021-03-22 /pmc/articles/PMC7982779/ /pubmed/33766727 http://dx.doi.org/10.1016/j.jamcollsurg.2021.02.019 Text en © 2021 by the American College of Surgeons. Published by Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Collective Review
Meizoso, Jonathan P.
Moore, Hunter B.
Moore, Ernest E.
Fibrinolysis Shutdown in COVID-19: Clinical Manifestations, Molecular Mechanisms, and Therapeutic Implications
title Fibrinolysis Shutdown in COVID-19: Clinical Manifestations, Molecular Mechanisms, and Therapeutic Implications
title_full Fibrinolysis Shutdown in COVID-19: Clinical Manifestations, Molecular Mechanisms, and Therapeutic Implications
title_fullStr Fibrinolysis Shutdown in COVID-19: Clinical Manifestations, Molecular Mechanisms, and Therapeutic Implications
title_full_unstemmed Fibrinolysis Shutdown in COVID-19: Clinical Manifestations, Molecular Mechanisms, and Therapeutic Implications
title_short Fibrinolysis Shutdown in COVID-19: Clinical Manifestations, Molecular Mechanisms, and Therapeutic Implications
title_sort fibrinolysis shutdown in covid-19: clinical manifestations, molecular mechanisms, and therapeutic implications
topic Collective Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7982779/
https://www.ncbi.nlm.nih.gov/pubmed/33766727
http://dx.doi.org/10.1016/j.jamcollsurg.2021.02.019
work_keys_str_mv AT meizosojonathanp fibrinolysisshutdownincovid19clinicalmanifestationsmolecularmechanismsandtherapeuticimplications
AT moorehunterb fibrinolysisshutdownincovid19clinicalmanifestationsmolecularmechanismsandtherapeuticimplications
AT mooreerneste fibrinolysisshutdownincovid19clinicalmanifestationsmolecularmechanismsandtherapeuticimplications

Ejemplares similares